Indivior Pharmaceuticals, Inc. Operating Income
Indivior Pharmaceuticals, Inc. (INDV) reported Operating Income of $160.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-03
- Indivior Pharmaceuticals, Inc. operating income (loss) for the quarter ending 2026-06-30 was $160.00M, a 122.22% increase year-over-year.
- Indivior Pharmaceuticals, Inc. operating income (loss) for the quarter ending 2026-03-31 was $137.00M, a 107.58% increase year-over-year.
- Indivior Pharmaceuticals, Inc. operating income (loss) for the quarter ending 2025-12-31 was $81.00M, a 76.09% increase year-over-year.
- Indivior Pharmaceuticals, Inc. operating income (loss) for the quarter ending 2025-09-30 was $43.00M, a 22.86% increase year-over-year.
- Indivior Pharmaceuticals, Inc. operating income (loss) for fiscal 2025 was $262.00M, a 589.47% increase from fiscal 2024.
- Indivior Pharmaceuticals, Inc. operating income (loss) for fiscal 2024 was $38.00M.
- Indivior Pharmaceuticals, Inc. operating income (loss) for fiscal 2023 was -$152.00M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month | Operating Income (Loss) 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $160.00M 10-Q · filed 2026-08-03 | $297.00M 10-Q · filed 2026-08-03 | $378.00M derived: sum of 3 quarters · filed 2026-08-03 | $421.00M derived: sum of 4 quarters · filed 2026-08-03 | |
| 2026-03-31 | $137.00M 10-Q · filed 2026-04-30 | $218.00M derived: sum of 2 quarters · filed 2026-04-30 | $261.00M derived: sum of 3 quarters · filed 2026-04-30 | $333.00M derived: sum of 4 quarters · filed 2026-08-03 | |
| 2025-12-31 | $81.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $124.00M derived: sum of 2 quarters · filed 2026-02-26 | $196.00M derived: sum of 3 quarters · filed 2026-08-03 | $262.00M 10-K · filed 2026-02-26 | |
| 2025-09-30 | $43.00M 10-Q · filed 2025-10-30 | $115.00M derived: sum of 2 quarters · filed 2026-08-03 | $181.00M 10-Q · filed 2025-10-30 | $227.00M derived: sum of 4 quarters · filed 2026-08-03 | |
| 2025-06-30 | $72.00M 10-Q · filed 2026-08-03 | $138.00M 10-Q · filed 2026-08-03 | $184.00M derived: sum of 3 quarters · filed 2026-08-03 | $219.00M derived: sum of 4 quarters · filed 2026-08-03 | |
| 2025-03-31 | $66.00M 10-Q · filed 2026-04-30 | $112.00M derived: sum of 2 quarters · filed 2026-04-30 | $147.00M derived: sum of 3 quarters · filed 2026-04-30 | $29.00M derived: sum of 4 quarters · filed 2026-04-30 | |
| 2024-12-31 | $46.00M 10-K · filed 2026-02-26 | $81.00M derived: sum of 2 quarters · filed 2026-02-26 | -$37.00M derived: sum of 3 quarters · filed 2026-02-26 | $38.00M 10-K · filed 2026-02-26 | $32.00M 10-K · filed 2025-03-03 |
| 2024-09-30 | $35.00M 10-K · filed 2026-02-26 | -$83.00M derived: sum of 2 quarters · filed 2026-02-26 | -$8.00M 10-Q · filed 2025-10-30 | ||
| 2024-06-30 | -$118.00M 10-K · filed 2026-02-26 | -$43.00M 10-Q · filed 2025-07-31 | |||
| 2024-03-31 | $75.00M 10-K · filed 2026-02-26 | ||||
| 2023-12-31 | -$152.00M 10-K · filed 2026-02-26 | -$156.00M 10-K · filed 2025-03-03 | |||
| 2022-12-31 | -$77.00M 10-Q · filed 2025-10-30 | -$81.00M 10-K · filed 2025-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |